Accordingly, George et al. even classified LCNEC as type I (biallelic TP53 and STK11/KEAP1 alterations) and type II (biallelic mutations of TP53 and RB1, 20]. This evidence concerns the gene KEAP1 and large cell neuroendocrine carcinoma.